All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IkT-148x
Therapeutic Area: Neurology Product Name: IkT-148x
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
IkT-148x is c-Abl kinase inhibitor for treatment of Parkinson's disease and multiple system atrophy. A study revealed that c-Abl activates and regulates alpha-synuclein aggregation in the brains of MSA patients and in the brains of animal models of the disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): QRA-244
Therapeutic Area: Neurology Product Name: QRA-244
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Details:
Poster titled "QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients " wail be presented MNDA 31st International Symposium on ALS/MND.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bryostatin 1,Tretinoin
Therapeutic Area: Neurology Product Name: APH-1104
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
The combination therapeutic consists of biodegradable polymer nanospheres co-encapsulating a Bryoid and a Retinoid to improve synergistically alpha-secretase (α-secretase) production and reduce -amyloid plaque generation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rGDF11
Therapeutic Area: Neurology Product Name: rGDF11
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Prime Movers Lab
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 24, 2020
Details:
Proceeds from the equity financing will enable Elevian to advance recombinant GDF11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV Vector based gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding November 10, 2020
Details:
Funding will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Poster titled "Therapeutic efficacy of a small molecule inhibitor targeting tau self-association in mouse models of tauopathy" will be presented at the 13th Clinical Trials on Alzheimer’s Disease Conference 2020 Digital Event.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SLS-007
Therapeutic Area: Neurology Product Name: SLS-007
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
SLS-007 Targets Intracellular Alpha-Synuclein Aggregates in Parkinson's Disease. Preliminary Data From In Vivo Preclinical Study of SLS-007 Expected in Q1 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,360.0 million Upfront Cash: $135.0 million
Deal Type: Acquisition October 15, 2020
Details:
Acquisition expands Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's promising preclinical SARM1 programs for axonal degeneration .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Funapide
Therapeutic Area: Neurology Product Name: FX301
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Golimumab
Therapeutic Area: Neurology Product Name: ION373
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
ION373 is an Ionis-owned investigational antisense medicine designed to stop the mutated gene from producing excess GFAP. Earlier this year, the European Medicines Agency (EMA) granted orphan drug designation to ION373.
</
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
